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Abstract
Background: Low molecular weight heparins hold several advantages over unfractionated heparin
including convenience of administration. Enoxaparin is one such heparin licensed in the UK for use
in unstable coronary artery disease (unstable stable angina and non-Q wave myocardial infarction).
In these patients, two large randomised controlled trials and their meta-analysis showed small
benefits for enoxaparin over unfractionated heparin at 30–43 days and potentially at one year.
We found no relevant published full economic evaluations, only cost studies, one of which was
conducted in the UK. The other studies, from the US, Canada and France, are difficult to interpret
since their resource use and costs may not reflect UK practice.
Methods: We aimed to compare the benefits and costs of short-term treatment (two to eight
days) with enoxaparin and unfractionated heparin in unstable coronary artery disease. We used
published data sources to estimate the incremental cost per quality adjusted life year (QALY),
adopting a NHS perspective and using 1998 prices.
Results: The base case was a 0.013 QALY gain and net cost saving of £317 per person treated
with enoxaparin instead of unfractionated heparin. All but one sensitivity analysis showed net
savings and QALY gains, the exception (the worst case) being a cost per QALY of £3,305. Best
cases were a £495 saving and 0.013 QALY gain, or a £317 saving and 0.014 QALY gain per person.
Conclusions: Enoxaparin appears cost saving compared with unfractionated heparin in patients
with unstable coronary artery disease. However, cost implications depend on local
revascularisation practice.
Background
Advantages of low molecular weight heparins over un-
fractionated heparin include convenience of administra-
tion, higher bioavailability and the lack of need for
monitoring. Some varieties are now used in the treat-
ment of unstable angina and non-Q wave myocardial in-
farction (henceforth referred to as unstable coronary
artery disease). These conditions are common in hospital
and may be increasing. Incidence of unstable angina
ranges from 99 to 246 per 100,000[1,2] and approxi-
mately 20–38% of myocardial infarctions are non-Q-
wave [3].
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A recent meta-analysis [4] compared low molecular
weight heparins (enoxaparin, dalteparin and
nadroparin) with unfractionated heparin in unstable
coronary artery disease. The short-term treatment com-
parison combined the results from 5 randomised con-
trolled trials (12,169 patients). The overall result
suggested that the low molecular varieties were no more
effective than unfractionated heparin, odds ratio 0.88
(95% confidence intervals 0.69–1.12), for the combined
outcome of death or myocardial infarction. This was con-
troversial as the meta-analysis used outcomes at the end
of equal duration of treatment, but this varied across the
trials. In addition, some authors [5] felt that it was inap-
propriate to combine the different varieties due to their
pharmacological differences, despite the lack of statisti-
cal heterogeneity detected between the trials.
Our current analysis considered only enoxaparin. This
variety is licensed in the UK for unstable coronary artery
disease and has the largest body of research evidence.
Two large randomised controlled trials [6,7] and their
meta-analysis [8] (comprising 7081 patients) showed
small relative benefits for enoxaparin over unfractionat-
ed heparin at 30–43 days and potentially at one year [9].
This was for the primary composite outcome of death,
myocardial infarction, recurrent angina or revascularisa-
tion (coronary artery bypass grafting and percutaneous
transluminal coronary angioplasty, PTCA). A third small
randomised controlled trial [10], reported in an abstract,
found mostly worse outcomes for the enoxaparin group.
We found no published full economic evaluations of
enoxaparin compared with unfractionated heparin, only
cost studies, one of which was conducted in the UK [11].
The other studies, from the US [12], Canada [13,14] and
France [4], are difficult to interpret since their resource
use and unit costs may not reflect UK practice and simple
currency conversions can markedly affect overall costs.
However, for information, their results in their base cur-
rency and when converted to UK pounds are summa-
rised in Table 1. It should be noted that the studies are
not directly comparable as, for example, they include dif-
ferent cost items, different patient groups (in some cases
using effectiveness estimates from country sub-groups),
and different cost years. The current study builds on our
previous work for the former South East/South West De-
velopment and Evaluation Committee [15], but includes
more extensive analyses and incorporates the most re-
cent published evidence.
This study aimed to compare the benefits and costs of
short-term treatment (two to eight days) with enoxa-
parin or unfractionated heparin in the treatment of un-
stable coronary artery disease, using published data
sources to model cost-utility. We chose to perform a cost-
utility rather than cost-effectiveness analysis because
there were several outcomes of interest (namely death,
myocardial infarction and recurrent angina). Multiple
outcomes can be combined through cost-utility analyses.
A further advantage over cost-effectiveness is that the
outcome of the cost-utility analysis is a cost per quality
adjusted life year (QALY) that incorporates both quality
and length of life. This also makes it is possible to com-
pare within and across treatment areas (although rank-
ings are potentially misleading where methods and
settings differ) [16,17]. The analysis adopted a National
Health Service (NHS) perspective, since the purpose was
to assist NHS decision-makers in the UK.
Methods
Effectiveness
To assess the benefits and harms of enoxaparin, we
searched the Cochrane Library, Medline and Embase for
randomised controlled trials. Two large double-blind tri-
als [6,7] and a third small randomised trial [10] were
found. Full details of the searches, inclusion criteria, ap-
praisal and data extraction methods and tables of results
are available in the Additional Material 1: Section A  and
Additional material 3: Section C 
The first trial [6] compared two to eight days treatment
using enoxaparin or unfractionated heparin. The prima-
ry composite outcome of death, myocardial infarction or
recurrent angina at 14 days was more common in the un-
fractionated heparin group, a difference maintained at
one year (relative risk reduction 16.2% P = 0.02 [6] and
10.7% P = 0.02 [9] respectively). Similarly, more revas-
cularisations (coronary artery bypass grafting or PTCA)
were required in the unfractionated heparin group at 30
days and one year.
The second trial [7] included two comparisons; enoxa-
parin or unfractionated heparin to eight days, followed
by enoxaparin or placebo to 43 days. At eight days, the
triple endpoint (death, recurrent myocardial infarction
or urgent revascularisation) was more frequent in the
unfractionated heparin group (relative risk reduction
14.6% P = 0.048).
Both were good quality trials, scoring five and three on
the Jadad scale [18]. The following limitations were de-
tected in one study [7]; incomplete description of with-
drawals and modification of inclusion criteria during the
trial. Their meta-analysis [8] found the enoxaparin
group's composite endpoint was significantly reduced to
43 days. However, the only outcome reported separately
was death and so these results could not be used in the
cost-utility model.BMC Cardiovascular Disorders 2001, 1:2 http://www.biomedcentral.com/1471-2261/1/2
The third trial [10] was a small randomised controlled
trial, but only reported in an abstract. It found mostly
worse outcomes for the enoxaparin group, but differenc-
es were not statistically significant and the trial was un-
der powered. The study did not appear to be double
blind, and although patients were followed up for 30
days it was unclear when the outcomes had been meas-
ured. For these reasons it was not possible to extract data
for the model.
In order to quantify the benefits from treatment we used
the individual components of the composite outcome al-
though the latter were not statistically significant. The
base case used the first trial's most severe event rates to
one year [9]. We estimated mean event free times gained
for deaths, myocardial infarctions and recurrent angina
using survival analysis techniques (actuarial method) to
estimate the area between the survival curves. Sensitivity
analyses used all events or the second trial's results [7]
assuming event rates at 43 days were maintained to one
year, as in the first trial (see Table 2).
Quality of life
Mean health-related quality of life changes associated
with death, myocardial infarction and recurrent angina
were based on preference weights of patients with sus-
pected myocardial infarction [19] (full details in Addi-
tional material 2: Section B). We combined these with
the mean event free times to estimate the QALYs gained
by treatment.
Resource use and costs
All costs were in 1998 UK pounds and since data were
only modelled for one year, discounting was unneces-
sary. The valuation of treatment-related costs and sav-
ings and average and minimum/maximum values used
in the base case and sensitivity analyses are shown in the
Additional material 2: Section B. To ensure generalisa-
bility within the UK, we used national costs supplement-
ed by local costs (or resource use information) where
necessary.
Table 3 shows how the cost difference between enoxa-
parin and unfractionated heparin was reduced when ad-
Table 1: Results of economic (cost) studies
Country UK [11] US [12] US [12] Canadian [14] Canadian [13] French [4] French [4]
Cost year ? (1996–1997) ? (1994–1996) 
1995*
? (1994–1996) 
1995*
1997 1999 1996 1996
Patient group UK only (n = 
191)
US only (n = 
936)
All ESSENCE 
patients
Canadian only 
(n = 1259
Canadian hypo-
thetical cohort
French only (n 
= 133)
All ESSENCE 
patients
Cost-effectiveness 
assessed at
30 days 30 days 30 days 1 year 30 days 30 days 30 days
Currency £UK $US $US $CAN $CAN FF FF
Cost savings
Base case 1 23.68 763 661 1485 44 9993 1555
Base case 2 na 1172 688 na na 2804 1014
Sensitivity analysis best 
case
Not available 
for cost differ-
ences
Net costs in 
only 14%**and 
6%*** of 200 
Not available 3167 435 12019 1876
Sensitivity analysis 
worst case
bootstrap sam-
ples
-174 -299 1518 542
In £UK (in cost year 
as above)
Base case 1 23.68 499 432 812 25 980 152
Base case 2 na 766 450 na na 275 99
Sensitivity analysis best 
case
Not available 
for cost differ-
ences
Net costs in 
only 14%** and 
6%*** of 200
Not available 1733 247 1178 184
Sensitivity analysis 
worst case
bootstrap sam-
ples
-95. Net costs 
in only 3% of 
1000 bootstrap 
samples
-170 149 53
Notes ? means unclear na = not applicable Negative cost savings indicates a net cost * taken as 1995 for currency conversion ** initial hospitalisation *** 
cumulative total Cost savings converted to UK pounds using Purchasing Power Parities (PPP) [23] (this eliminates the differences in price levels between 
countries). ESSENCE patients were the patients in the 'Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events' trial [6]BMC Cardiovascular Disorders 2001, 1:2 http://www.biomedcentral.com/1471-2261/1/2
ministration costs were included. Other differences in
resource use associated with enoxaparin treatment are
summarised in Table 2.
We assumed that the cost per day for the length of stay
included resource use for adverse events such as haem-
orrhage. Outpatient follow-up, ambulance transport and
non-NHS costs were excluded. Where required (model 3
– see below), treatment costs of myocardial infarction
and recurrent angina were based on resource use of the
most severe event at one year from one trial [9] for the
base case and all events for the upper value.
Model and sensitivity analyses
The sources of the base case and ranges used in the anal-
yses are shown in the Additional Materials:
Section B. We combined these data to estimate the incre-
mental cost per QALY of enoxaparin compared with un-
fractionated heparin treatment based on the following
three scenarios:
1. Base case: Difference in treatment-related costs minus
potential savings (from revascularisations (coronary ar-
tery bypass grafting and angioplasty) and length of stay).
Table 2: Base case and ranges of efficacy, quality of life, resource use and cost data used (amalgamation of all models)
Base case Lower, Upper
Effectiveness data
Mean event free years. Values used in sets, not individually for each out-
come.
Life years gained 0.010 0.002, same as base case
Myocardial infarction free time gained 0.007 0.008, 0.013
Time free from recurrent angina 0.018 0.014, 0.022
Quality of life data
Values used in sets, not individually for each outcome. Quality of
life change associated with
Death 0.977 same as base case, no upper
myocardial infarction (Q-wave) 0.160 0.102, no upper
Non-Q-wave myocardial infarction 0.088 0.056, no upper
Resource use (per person)
Treatment duration (days) 2.6 2,8
Coronary artery bypass grafting rates at one year 0.014 -0.013,0.041
Angioplasty rates at one year 0.042 0.014, 0.070
Length of stay at 30 days (days) 0.40 -0.50, 0
Myocardial infarction rates at one year (Model 3 only) 0.006 same as base case, 0.013
Recurrence of angina at one year (Model 3 only) 0.017 same as base case, 0.021
Drug treatment costs per person1
Enoxaparin, drug alone per day £12.16 £9.00, £14.29
Unfractionated heparin loading dose & saline flush £0.52 £0.41, £0.73
Consumables for loading dose £0.14 same as base case, £0.16
Unfractionated heparin drawn-up in saline per day £1.83 £1.37, £2.46
Pump-related costs per day £1.79 £1.27, £2.54
Monitoring (aPTT tests) per day £3.67 0, £3.81
Difference in nursing time between enoxaparin and £3.39 £2.95, £4.36
unfractionated heparin (cost over 2.6 days)
Treatment costs (per person)
(*including length of stay)
Coronary artery bypass grafting* £6,534 £5,933, £6,952
Angioplasty* £1,803 £1,647, £2,823
Treatment of acute myocardial infarction* (Model 3 only) £1,150 £863, £1,385
Treatment of angina* (Model 3 only) £549 £418, £758
Per in-patient day £399 £196, same as base case
Notes: 1 Upper value includes VAT where appropriate.BMC Cardiovascular Disorders 2001, 1:2 http://www.biomedcentral.com/1471-2261/1/2
2. As for scenario 1, but including Value Added Tax (VAT
at 17.5%), National Insurance and superannuation (ie
transfer payments) since the NHS must pay these.
3. As for scenario 1, but including treatment costs of car-
diac events (myocardial infarctions and recurrent angi-
na) instead of differences in length of stay. The unit costs
for length of stay should be interpreted with caution due
to somewhat arbitrary accounting. This scenario was
used to determine whether the alternative approach
(treatment of cardiac events) produced much difference.
One-way sensitivity analyses were performed to deter-
mine how robust estimates were to the assumptions.
Results
The base case was associated with a QALY gain of 0.013
and negative net costs (ie cost savings) of £317 for each
person treated with enoxaparin instead of unfractionat-
ed heparin. Table 4 shows the range of incremental net
costs and QALYs resulting from the scenarios and one-
way sensitivity analyses. There were net cost savings and
QALY gains in all but one case. The latter was due to the
longer length of stay for the UK cohort [6] that resulted
in a net cost of £42 and hence cost per QALY of £3,305.
However, there was still a net cost saving (£158) if there
was no difference in length of stay.
Results were robust to changes in treatment duration
and related costs, and the unit cost of coronary artery by-
pass grafting. Results were moderately sensitive to
changes in the unit cost of angioplasty and very sensitive
to variation in rates of revascularisation, and the dura-
tion and unit cost of length of stay. Similarly, using dif-
ferences in treatment costs for myocardial infarctions
and recurrent angina instead of the mean length of stay
(third scenario) had a large impact on net cost savings.
Changes in mean event free times reduced the QALY gain
by up to three fold.
Table 3: Drug and administration costs for enoxaparin and unfractionated heparin
Average costs excluding VAT Unfractionated Enoxaparin Difference
heparin
Daily costs
Drug alone £0.95 £12.16 £11.21
Administration (saline, consumables, intra-venous pump; 
monitoring; nursing time)
£7.52 na £7.52
Total cost £8.47 £12.16 £3.69
Loading dose
Drug alone £0.29 na £0.29
Administration £0.70 na £0.70
Total cost £0.99 na £0.99
Total treatment costs for base case (2.6 days) £23.02 £31.62 £8.60
Table 4: Range of net costs and QALYs resulting from scenarios and one-way sensitivity analyses
QALY or cost per person
Item varied Lower Upper
Base case (per person): not applicable not applicable
QALY gain 0.013
Net cost -£317 (ie cost saving for enoxaparin)
Event free time gained 0.004 QALYs 0.014 QALYs
Quality of life associated with event 0.012 QALYs na
Treatment duration -£298 -£320
Length of stay
Difference in length of stay £42 (ie £3,305/QALY) -£158
Cost per length of stay -£236 na
RevascularisationsBMC Cardiovascular Disorders 2001, 1:2 http://www.biomedcentral.com/1471-2261/1/2
Discussion
Enoxaparin treatment compared with unfractionated
heparin was cost saving with increased effectiveness for
the base case. Only one sensitivity analysis produced a
net cost (£42 per person, cost per QALY of £3,305). The
maximum cost saving per person was £495 (with a 0.013
QALY gain).
The other UK study [11] found net cost savings of £23.68
per person in contrast to the £317 in the present study.
This appears to be due to the use of alternative unit costs
for revascularisations and length of stay, further rein-
forcing the sensitivity of the results to these variables.
Perhaps paradoxically, in the first trial [6], the UK enox-
aparin sub-group had a longer length of stay than the un-
fractionated heparin group, although the authors of the
US study [12] suggested that enoxaparin may have
helped save the sickest patients who therefore required
more treatment.
Interpretation from an UK viewpoint of the other eco-
nomic studies [4,12–14] is difficult due to their resource
use and unit costs being potentially unrepresentative of
the UK and the variation in cost year (possibly 1994–
1999). All these studies were based on the first trial [6]
and used outcomes at 30 days in all but on case [14]. In
contrast, we used results from the second large trial [7]
to inform the sensitivity analysis. In addition, sub-group
analyses of patients by country are also problematic
since the trials were powered for a triple composite of
death, myocardial infarction and recurrent angina (or
urgent revascularisation). They were not powered for
cost outcomes or to detect country differences. Further-
more, unlike the other cost studies, ours was a full eco-
nomic evaluation.
As noted before, the studies are not directly comparable.
However, the majority of results from the other studies
were also cost saving with a maximum of £1,733 (in the
Canadian patient sub-group [14]). In a minority of re-
sults there were net costs [12–14] with a maximum re-
ported cost of £170 per person [13].
Our study results were moderately sensitive to changes
in the unit cost of angioplasty and very sensitive to vari-
ation in rates of PTCA. This was similar to both the
French study [4] and Canadian sub-group study [13].
Our results were also very sensitive to variation in the
duration and unit cost of length of stay. This was also
found in the French study [4] for both stay in the inten-
sive care unit and non-intensive care for the ESSENCE
[6] patients and French sub-group respectively. In our
third scenario, similarly to the Canadian sub-group
study [13], results were particularly affected by changes
in the composite end-point. These similarities are unsur-
prising given that all the studies used data from one trial.
Limitations of the study
All models have limitations. These can be separated into
general modelling issues and those specific to the current
study.
There are three general limitations of modelling, all of
which may be relevant here. Firstly, the potential biases
from amalgamation of multiple data sources (in this
study effectiveness, quality of life and costs). Secondly,
Difference in coronary artery bypass grafting rates -£140 -£495
Difference in angioplasty rates -£242 -£368
Cost of coronary artery bypass grafting -£309 -£323
Cost of angioplasty -£311 -£360
Unfractionated heparin costs
Unfractionated heparin loading dose and saline flush -£314 -£318
Unfractionated heparin drawn-up in saline -£313 -£318
Pump-related -£312 -£318
Monitoring (activate partial thromboplastin time tests) -£308 -£318
Nursing time -£314 -£318
Enoxaparin costs -£314 -£326
Scenario 3: Treatment of cardiac events
(not mean length of stay)
Myocardial infarction rate and recurrence of angina -£174 -£184
Cost to treat acute myocardial infarction -£181 -£187
Cost to treat angina -£181 -£189
Notes: See Table 2 for ranges used. As there was little difference between scenarios 1 and 2, we amalgamated the results. Negative net costs indi-
cate cost saving if using enoxaparin. Net costs and QALY gains are not shown where unaffected by parameter changes. na means not avaliable.
Table 4: Range of net costs and QALYs resulting from scenarios and one-way sensitivity analyses (Continued)BMC Cardiovascular Disorders 2001, 1:2 http://www.biomedcentral.com/1471-2261/1/2
the simplifications required may lead to models being
unrepresentative of reality. Thirdly, potentially inade-
quate sensitivity analyses where data variances are un-
known, that also may be applicable here and is discussed
below. Furthermore, external validity (generalisability)
may be weak as results used from international ran-
domised controlled trials reflect efficacy rather than ef-
fectiveness. Patient populations, staff in-puts, settings
and therapies that differ from the UK, compound this.
Shifts in other treatment or lifestyle aspects also influ-
ence relative effectiveness. For example, stent rates dur-
ing angioplasty have increased dramatically since the
trials, with improved results but additional costs.
The above limitations of modelling are not specific to this
study and are unavoidable in most models. Currently,
few models are subsequently validated due to lack of
time and resources for data collection and testing. How-
ever, alternatives – economic evaluations alongside tri-
als – are usually more expensive and are not always the
'gold standard' since resource use may not reflect routine
practice and they may be no more informative than mod-
elling. We do not believe that the study results would be
changed, although the magnitude of the potential sav-
ings may be smaller – an issue that we return to in the
Policy implications section.
A main limitation of the current study was that sensitiv-
ity analyses for treatment-related costs principally in-
volved variation in unit costs as ranges for resource use
were unavailable. Furthermore, the one-way analyses
risked missing possible interactions between variables.
The overall effectiveness estimated in the model was
from randomised controlled trials rather than the UK
sub-group. There was some variation in effectiveness (eg
revascularisation rates) between country sub-groups.
However, this was not a prior hypothesis (ie post hoc
finding) and to assume that such differences were genu-
ine could have been seriously misleading. The extent of
certainty around the effectiveness data was unknown as
the simple survival analysis to estimate mean event free
times did not take into account censoring and confidence
intervals could not be calculated. Similarly, the small
range of QALY gains (0.004 to 0.014) reflected limited
data available rather than a true effect as it was not pos-
sible to calculate confidence intervals for the mean
changes in quality of life from the source study [19].
Longer-term data were also unavailable and so extrapo-
lation from 100 days to one year was based on assump-
tions. In addition, the quality of life estimates were not
derived in an ideal manner as they used the Rosser clas-
sification [20]. Although widely used, this classification
is not based on choice (the 'gold standard' for measuring
preferences), it is insensitive to subtle changes [21] and
valuations are not exactly reproducible [22]. Nonethe-
less, these data were the best available as the only pub-
lished valuations found for the patient group in question.
There were also limitations in other resource use, eg the
lack of confidence intervals for nursing times, and sepa-
rate revascularisation rates from the second trial [7].
Furthermore, whilst most analyses used the most severe
event rates in order to avoid double counting, this risked
under-estimating QALYs and treatment-related costs for
cardiac events.
There are also drawbacks to the unit costs. These were
predominantly national costs, a heterogeneous group
(NHS hospitals and pay scales, and manufacturers, and
published sources) occasionally supplemented by local
costs. It is difficult to estimate what the impact of this
costing approach may be. The analysis shows enoxaparin
had a favourable economic impact under a wide range of
assumptions, however there were small differences be-
tween the alternatives that could be overturned by esti-
mation errors that may appear small in isolation.
Furthermore, the overheads element of the unit costs
(for administration, cleaning, electricity, etc.) involves
somewhat arbitrary accounting principles. Allocation
methods vary between hospitals and therefore cost dif-
ferences may not reflect true deviations. In addition,
contracted prices for drugs, especially non-patented un-
fractionated heparin, and consumables may be consider-
ably lower but are difficult to obtain, despite moves in the
NHS for greater openness about costs.
Policy implications
Given the robustness of the results to changes in as-
sumptions, a move from unfractionated heparin to enox-
aparin appears cost saving and more beneficial in this
patient group. We calculated full costs (ie including nurs-
ing time and a share of equipment costs (pumps)) that
reduce the overall cost difference between the two strat-
egies. However, this also involves a judgement on the op-
portunity cost of such components. Some potential cost
or resource use savings such as consumables and test re-
agents are clearly realisable. However, other savings (eg
staff and the hotel portion of hospital stays) depend on
the period of change and whether resources freed can be
redeployed efficiently or transferred between budget ar-
eas. Short-term increases or decreases in workload may
not equate to changes in staffing as people adapt, al-
though they may be released for other tasks. Similarly,
savings from pumps are not full realisable until purchase
of new ones, although there may be an impact on the staff
time involved in obtaining a pump if supplies are shared.
Whilst this evaluation adopted a NHS perspective to as-
sist decision-makers, this approach could be criticisedBMC Cardiovascular Disorders 2001, 1:2 http://www.biomedcentral.com/1471-2261/1/2
since a broader, societal view is less likely to reinforce ar-
tificial budgetary boundaries.
The purpose of this study was to consider the cost-utility
of enoxaparin since decision makers are facing the choice
of substituting the traditional unfractionated heparin.
However, dalteparin is another low molecular weight
heparin licensed in the UK, but the licensing arrange-
ments of other varieties is likely to be different on other
countries. Furthermore, this paper was prepared for
NHS decision makers and should not be generalised to
other health care systems without caution. We noted the
impact of revascularisation practices, but there may be
other differences in health care politics and reimburse-
ment.
Conclusions
Moving from unfractionated heparin to enoxaparin ap-
pears cost saving and more beneficial in patients with
unstable coronary artery disease, although cost implica-
tions depend on local revascularisation practice. Further
research is needed into the extent that potential savings
are realisable and the effect of treatment on risk strati-
fied groups as, with use, treatment thresholds may lower
thus increasing total spending without necessarily gain-
ing benefit.
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lines for reporting health economic papers http://www.bmj.com/cgi/content/
full/313/7052/275. Furthermore, this section allows readers to test the effect 
of substituting their own variables.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2261-1-
2-S2.doc]
Additional material 3: Section C: Data extrac-
tion tables for clinical trials
These have been added for completeness as they give full details (including 
comments about their quality) of the trials used for the effectiveness estimates.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2261-1-
2-S3.doc]BMC Cardiovascular Disorders 2001, 1:2 http://www.biomedcentral.com/1471-2261/1/2
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